Pfizer Inc. Stock
€26.75
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Pfizer Inc. | 0.940% | 0.564% | -7.118% | -45.497% | -44.131% | -23.908% | -26.881% |
Biogen Inc. | 0.720% | 3.061% | 2.680% | -18.846% | -13.254% | 9.189% | -22.576% |
Elanco Animal Health Inc. | 0.840% | 4.912% | 17.949% | 0.623% | 5.803% | -51.392% | - |
AbbVie Inc. | 1.600% | 5.159% | 4.525% | -11.854% | -8.912% | 55.906% | 79.883% |

sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.
*Pros: *
Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.
Comments
News

Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab). ELREFXIO is a targeted immunotherapy for the

Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication trend led by Ozempic, Novo Nordisk A/S (NYSE: NVO)